Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study

NACompletedINTERVENTIONAL
Enrollment

11,255

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

July 14, 2023

Conditions
Hypertension
Interventions
DRUG

Intensive BP treatment group

"Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"

DRUG

Standard BP treatment group

Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.

Trial Locations (1)

100087

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV

NCT04030234 - Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study | Biotech Hunter | Biotech Hunter